Finckh Axel, Zufferey Pascal, Schurch Marc-André, Balagué Federico, Waldburger Maurice, So Alexander K L
Section of Clinical Sciences, Division of Rheumatology, Immunology & Allergy, Department of Medicine, Brigham & Women's Hospital, Harvard Medical School, Boston, USA.
Spine (Phila Pa 1976). 2006 Feb 15;31(4):377-81. doi: 10.1097/01.brs.0000199917.04145.80.
STUDY DESIGN: Double-blinded randomized controlled trial. OBJECTIVE: To test the short-term efficacy of a single intravenous (IV) pulse of glucocorticoids on the symptoms of acute discogenic sciatica. SUMMARY OF BACKGROUND DATA: The use of glucocorticoids in the treatment of acute discogenic sciatica is controversial. A potential advantage of the IV pulse therapy is the ability to distribute high glucocorticoid concentrations to the area surrounding the prolapsed disc without the risks and inconveniences of an epidural injection. METHODS: Patients with acute sciatica (<6-week duration) of radiologically confirmed discogenic origin were randomized to receive either a single IV bolus of 500 mg of methylprednisolone or placebo. Clinical evaluation was performed in a double-blind manner on days 0, 1, 2, 3, 10, and 30. The primary outcome was reduction in sciatic leg pain during the first 3 days following the infusion; secondary outcomes were reduction in low back pain, global pain, functional disability, and signs of radicular irritation. The analysis was performed on an intent-to-treat basis using a longitudinal regression model for repeated measures. RESULTS: A total of 65 patients were randomized, and 60 completed the treatment and the follow-up assessments. A single IV bolus of glucocorticoids provided significant improvement in sciatic leg pain (P = 0.04) within the first 3 days. However, the effect size was small, and the improvement did not persist. IV glucocorticoids had no effect on functional disability or clinical signs of radicular irritation. CONCLUSIONS: Although an IV bolus of glucocorticoids provides a short-term improvement in leg pain in patients with acute discogenic sciatica, its effects are transient and have small magnitude.
研究设计:双盲随机对照试验。 目的:测试单次静脉注射糖皮质激素对急性椎间盘源性坐骨神经痛症状的短期疗效。 背景数据总结:糖皮质激素在急性椎间盘源性坐骨神经痛治疗中的应用存在争议。静脉脉冲疗法的一个潜在优势是能够将高浓度糖皮质激素输送到椎间盘突出周围区域,而无硬膜外注射的风险和不便。 方法:经影像学证实为椎间盘源性的急性坐骨神经痛(病程<6周)患者被随机分为两组,分别接受单次静脉推注500mg甲泼尼龙或安慰剂。在第0、1、2、3、10和30天以双盲方式进行临床评估。主要结局是输液后前3天坐骨神经痛的减轻;次要结局是腰痛、总体疼痛、功能障碍和神经根刺激体征的减轻。分析采用意向性分析,使用纵向回归模型进行重复测量。 结果:共有65例患者被随机分组,60例完成了治疗及随访评估。单次静脉推注糖皮质激素在第1个3天内可使坐骨神经痛显著改善(P=0.04)。然而,效应量较小,且改善未持续。静脉注射糖皮质激素对功能障碍或神经根刺激的临床体征无影响。 结论:虽然静脉推注糖皮质激素可使急性椎间盘源性坐骨神经痛患者的腿痛得到短期改善,但其效果是短暂的,且幅度较小。
Spine (Phila Pa 1976). 2006-2-15
Rheumatology (Oxford). 2005-11
J Am Board Fam Med. 2008
N Engl J Med. 1997-6-5
J Manipulative Physiol Ther. 2000-10
BMC Musculoskelet Disord. 2025-7-4
Cochrane Database Syst Rev. 2022-10-21
J Clin Med. 2022-8-31
Eur J Clin Pharmacol. 2022-9
Medicine (Baltimore). 2022-7-15
Medicina (Kaunas). 2019-11-14
Int Orthop. 2018-11-30